Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.59 |
| ▸ | PTP4A3 | O75365 | 5/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | NAT1 | P18440 | 1/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065590 | 1.00 | CISD1 (0.59) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL2065593 | 1.00 | CISD1 (0.59) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL10090248 | 0.92 | PTP4A3 (0.63) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL2065017 | 0.92 | PTP4A3 (0.63) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL2065018 | 0.92 | PTP4A3 (0.63) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL10090253 | 0.91 | PTP4A3 (0.65) | CISD1PTP4A3MMP3MMP13GSK3B | |
| SCHEMBL2064969 | 0.91 | PTP4A3 (0.65) | CISD1PTP4A3MMP3MMP13GSK3B | |
| SCHEMBL2064968 | 0.91 | PTP4A3 (0.65) | CISD1PTP4A3MMP3MMP13GSK3B | |
| SCHEMBL10090262 | 0.86 | CA2 (0.63) | CISD1PTP4A3MMP3MMP13CA2 | |
| SCHEMBL2066451 | 0.86 | CA2 (0.63) | CISD1PTP4A3MMP3MMP13CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | CISD1 4740/4885PTP4A3 28/4885MMP3 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.